Multicenter surveillance of species distribution and antifungal susceptibilities of Candida bloodstream isolates in South Korea.
Multicenter data on in vitro susceptibility of Candida bloodstream isolates to echinocandin antifungal agents is still lacking in South Korea. We performed a prospective multicenter study to determine the species distribution of Candida bloodstream isolates and their susceptibility to five antifungal agents, including caspofungin and micafungin. A total of 639 isolates were collected from 20 tertiary hospitals between September 2006 and August 2007. Antifungal susceptibilities were determined through the use of the CLSI broth microdilution method M27-A3. The overall species distribution was as follows; Candida albicans (38%), Candida parapsilosis (26%), Candia tropicalis (20%), Candida glabrata (11%), and miscellaneous Candida species (5%). Although C. parapsilosis and miscellaneous Candida species were less susceptible to both echinocandins, all 639 isolates were susceptible to both caspofungin and micafungin (MIC, <or= 2 microg/ml). Nearly all isolates (99.7%) had a MIC <or= 1 microg/ml to amphotericin B. Resistance to fluconazole and voriconazole was found in 0.8% and 0.3%, respectively, among all Candida isolates, with C. glabrata and C. krusei isolates displaying the greatest level of resistance. This is the largest multicenter candidemia study conducted in South Korea and shows that non-C. albicans Candida species, including C. parapsilosis, constitutes over 60% of all Candida species isolates recovered from the bloodstream. In addition, the rates of resistance to all five antifungals, including two echinocandins, are still low among bloodstream isolates in South Korea.
Jung
Sook-In
SI
Chonnam National University Medical School, Gwangju, South Korea.
Shin
Jong Hee
JH
Song
Jae-Hoon
JH
Peck
Kyong Ran
KR
Lee
Kyungwon
K
Kim
Mi-Na
MN
Chang
Hyun Ha
HH
Moon
Chi Sook
CS
D000935:Antifungal Agents / Q000627:therapeutic use; D002175:Candida / Q000187:drug effects* / Q000302:isolation & purification; D002177:Candidiasis / Q000188:drug therapy / Q000382:microbiology*; D025141:Drug Resistance, Fungal; D016469:Fungemia / Q000188:drug therapy / Q000382:microbiology*; D006801:Humans; D008826:Microbial Sensitivity Tests; D011159:Population Surveillance; D056910:Republic of Korea / Q000453:epidemiology
D000935:Antifungal Agents